Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $400.00

Krystal Biotech (NASDAQ:KRYS) had its price objective raised by Bank of America from $392.00 to $400.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s price target points to a potential upside of 20.01% from the stock’s current price.

Several other research firms also recently commented on KRYS. TD Cowen lifted their price target on shares of Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research report on Monday, July 13th. Citigroup boosted their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, Chardan Capital raised Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $365.80.

Krystal Biotech Price Performance

KRYS stock traded down $3.38 during mid-day trading on Monday, hitting $333.30. 73,604 shares of the stock were exchanged, compared to its average volume of 333,501. The stock has a market capitalization of $9.87 billion, a price-to-earnings ratio of 41.73 and a beta of 0.54. The business has a fifty day moving average price of $344.05 and a 200 day moving average price of $312.66. Krystal Biotech has a 12 month low of $158.08 and a 12 month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, equities analysts forecast that Krystal Biotech will post 7.48 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Thomas sold 1,000 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 51,000 shares of company stock worth $17,558,270 in the last three months. 13.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Silvant Capital Management LLC bought a new position in Krystal Biotech during the 2nd quarter valued at approximately $30,000. Integrated Wealth Concepts LLC bought a new stake in shares of Krystal Biotech in the 2nd quarter worth approximately $46,000. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech during the first quarter valued at approximately $34,000. USA Financial Formulas purchased a new position in shares of Krystal Biotech during the first quarter valued at approximately $44,000. Finally, Versant Capital Management Inc raised its holdings in shares of Krystal Biotech by 189.2% during the second quarter. Versant Capital Management Inc now owns 214 shares of the company’s stock valued at $80,000 after acquiring an additional 140 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.